GB201720426D0 - CD47 and BCMA antigen-binding molecules - Google Patents

CD47 and BCMA antigen-binding molecules

Info

Publication number
GB201720426D0
GB201720426D0 GBGB1720426.4A GB201720426A GB201720426D0 GB 201720426 D0 GB201720426 D0 GB 201720426D0 GB 201720426 A GB201720426 A GB 201720426A GB 201720426 D0 GB201720426 D0 GB 201720426D0
Authority
GB
United Kingdom
Prior art keywords
binding molecules
bcma antigen
bcma
antigen
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1720426.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hummingbird Bioscience Holdings Ltd
Original Assignee
Hummingbird Bioscience Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hummingbird Bioscience Holdings Ltd filed Critical Hummingbird Bioscience Holdings Ltd
Priority to GBGB1720426.4A priority Critical patent/GB201720426D0/en
Publication of GB201720426D0 publication Critical patent/GB201720426D0/en
Priority to US16/760,899 priority patent/US20220298254A1/en
Priority to EP18803566.1A priority patent/EP3704157A1/en
Priority to PCT/EP2018/079932 priority patent/WO2019110209A1/en
Priority to JP2020543394A priority patent/JP2021500926A/en
Priority to KR1020207014915A priority patent/KR20200079511A/en
Priority to CN201880071849.4A priority patent/CN111417653A/en
Priority to SG11202003943YA priority patent/SG11202003943YA/en
Priority to PCT/EP2018/079931 priority patent/WO2019086573A1/en
Priority to AU2018358004A priority patent/AU2018358004A1/en
Priority to CA3080860A priority patent/CA3080860A1/en
Priority to US17/847,020 priority patent/US11685789B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
GBGB1720426.4A 2017-11-01 2017-12-07 CD47 and BCMA antigen-binding molecules Ceased GB201720426D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB1720426.4A GB201720426D0 (en) 2017-12-07 2017-12-07 CD47 and BCMA antigen-binding molecules
CA3080860A CA3080860A1 (en) 2017-11-01 2018-11-01 Cd47 antigen-binding molecules
JP2020543394A JP2021500926A (en) 2017-11-01 2018-11-01 CD47 antigen-binding molecule
EP18803566.1A EP3704157A1 (en) 2017-11-01 2018-11-01 Cd47 antigen-binding molecules
PCT/EP2018/079932 WO2019110209A1 (en) 2017-12-07 2018-11-01 Cd47 and bcma/taci antigen-binding molecules
US16/760,899 US20220298254A1 (en) 2017-11-01 2018-11-01 Cd47 antigen-binding molecules
KR1020207014915A KR20200079511A (en) 2017-11-01 2018-11-01 CD47 antigen-binding molecule
CN201880071849.4A CN111417653A (en) 2017-11-01 2018-11-01 CD47 antigen binding molecules
SG11202003943YA SG11202003943YA (en) 2017-11-01 2018-11-01 Cd47 antigen-binding molecules
PCT/EP2018/079931 WO2019086573A1 (en) 2017-11-01 2018-11-01 Cd47 antigen-binding molecules
AU2018358004A AU2018358004A1 (en) 2017-11-01 2018-11-01 CD47 antigen-binding molecules
US17/847,020 US11685789B2 (en) 2017-11-01 2022-06-22 CD47 antigen-binding molecules

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1720426.4A GB201720426D0 (en) 2017-12-07 2017-12-07 CD47 and BCMA antigen-binding molecules

Publications (1)

Publication Number Publication Date
GB201720426D0 true GB201720426D0 (en) 2018-01-24

Family

ID=61007145

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1720426.4A Ceased GB201720426D0 (en) 2017-11-01 2017-12-07 CD47 and BCMA antigen-binding molecules

Country Status (2)

Country Link
GB (1) GB201720426D0 (en)
WO (1) WO2019110209A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112661855B (en) * 2019-10-16 2022-09-13 尚健单抗（北京）生物技术有限公司 Fusion protein containing SIRPa variant
AU2021268033A1 (en) 2020-05-08 2022-12-15 Alpine Immune Sciences, Inc. APRIL and BAFF inhibitory immunomodulatory proteins with and without a T cell inhibitory protein and methods of use thereof
US20230374147A1 (en) * 2020-11-02 2023-11-23 Hummingbird Bioscience Pte. Ltd. Bcma/taci antigen-binding molecules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3415531T3 (en) * 2011-05-27 2023-09-18 Glaxo Group Ltd BCMA (CD269/TNFRSF17)-BINDING PROTEINS
US10752665B2 (en) * 2014-02-27 2020-08-25 Ucl Business Ltd April variants
UA126146C2 (en) * 2015-09-18 2022-08-25 Арч Онколоджі, Інк. Therapeutic cd47 antibodies
EP3165536A1 (en) * 2015-11-09 2017-05-10 Ludwig-Maximilians-Universität München Trispecific molecule combining specific tumor targeting and local immune checkpoint inhibition
EP3615068A1 (en) * 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor

Also Published As

Publication number Publication date
WO2019110209A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
SG11202003943YA (en) Cd47 antigen-binding molecules
IL313163A (en) Multispecific antigen-binding molecules and uses thereof
IL269534A (en) Chimeric molecules and uses thereof
IL260937A (en) Fabs-in-tandem immunoglobulin and uses thereof
IL254223A (en) Cd20 binding molecules and uses thereof
EP3331549A4 (en) Improved microbe-binding molecules and uses thereof
GB201615617D0 (en) Small molecules
HK1248721A1 (en) Antibody molecules and uses thereof
GB201601075D0 (en) Antibodies molecules
SG10201912366YA (en) Anti-cd3 antibody and molecules comprising the antibody
ZA201806597B (en) Ilt7 binding molecules and methods of using the same
GB201522391D0 (en) Antibody molecules
DK3110447T3 (en) Anti-EGFR antibody and its applications
DK3417058T3 (en) Sortase-modified molecules and their uses
HK1259331A1 (en) Compact flowmeter and related method
EP3432127A4 (en) Input element and input device
DK2977201T3 (en) METAL AND MAGNETIC-REOLOGICAL MULTI PANEL
IL278832A (en) Optimized gp41-binding molecules and uses thereof
DK3152305T3 (en) PROLINE SPECIFIC ENDOPROTEASE AND APPLICATION THEREOF
GB201720426D0 (en) CD47 and BCMA antigen-binding molecules
GB201621591D0 (en) Antibody molecules and method
GB201612714D0 (en) Input device and steering input device
IL252932A0 (en) Anti-cxcl12 antibody molecules and their uses
GB201720425D0 (en) CD47 and CD33 antigen-binding molecules
GB201718101D0 (en) CD47 and CD33 Antigen-binding molecules

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)